November 15, 2021
LIPAC ONCOLOGY TO PRESENT TWO-YEAR DATA FOR PHASE 1/2A Study of LIPAX AT THE 22ND ANNUAL MEETING OF THE SOCIETY OF UROLOGIC ONCOLOGY More…
October 7,2021
LIPAC ONCOLOGY SECURES BROAD PATENT PROTECTION FOR PROLIPOSOMAL PACLITAXEL COMPOSITIONS FORMULATED FOR DELIVERY TO THE BLADDER AND URETER FOR THE TREATMENT OF SOLID TUMOR CARCINOMAS More…
September 21, 2021
LIPAC ONCOLOGY TO PRESENT AT UPCOMING INVESTOR CONFERENCES More…
June 9, 2021
LIPAC ONCOLOGY ANNOUNCES TWO-YEAR RECURRENCE FREE SURVIVAL DATA FOR PHASE 1/2A STUDY OF LIPAX IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER More…
May 13, 2021
LIPAC ONCOLOGY NAMES DANIEL K. SPIEGELMAN AS INDEPENDENT BOARD ADVISOR More…
May 6, 2021
LIPAC ONCOLOGY ANNOUNCES APPOINTMENT OF JOSH HAMERMESH TO THE BOARD OF DIRECTORS More…
April 29, 2021
LIPAC ONCOLOGY ANNOUNCES SUCCESSFUL TYPE B MEETING WITH THE U.S. FDA FOR THE STUDY OF LIPAX FOR NON-MUSCLE INVASIVE BLADDER CANCER More…
December 10, 2020
LIPAC ONCOLOGY ANNOUNCES MAJOR PARTNERING MILESTONE ACHIEVED IN ITS LICENSE AGREEMENT WITH HUONS CO., LTD. More…
September 8, 2020
LIPAC ONCOLOGY ANNOUNCES COMPLETION OF PHASE 2A CLINICAL TRIAL OF LIPAX IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER More…
May 18, 2020
LIPAC ONCOLOGY ANNOUNCES PRESENTATION OF DATA FROM PHASE 1/2A STUDY OF LIPAX IN PATIENTS WITH HIGHLY RECURRENT BLADDER CANCER More…
January 12, 2020
LIPAC ONCOLOGY ANNOUNCES ACCEPTANCE OF AN ABSTRACT FOR PRESENTATION AT THE AMERICAN UROLOGICAL ASSOCIATION ANNUAL MEETING IN MAY 2020 More…
October 25, 2019
LIPAC ONCOLOGY ANNOUNCES SUCCESSFUL COMPLETIONS OF PHASE 1 BLADDER CANCER CLINICAL STUDY AND INITIATION OF PHASE 2A STUDY More…
September 16, 2019
LIPAC ONCOLOGY AND HUONS CO. ANNOUNCE EXCLUSIVE LICENSING AGREEMENT FOR TBC-1002 IN KOREA More…
January 9, 2017
TESORX ANNOUNCES CREATION OF LIPAC ONCOLOGY AND ADVANCEMENT OF ONCOLOGY PIPELINE More…